End-of-day quote
Taipei Exchange
23:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
60.6
TWD
|
-1.78%
|
|
-0.49%
|
-12.68%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
27,095
|
24,833
|
26,213
|
22,680
|
15,831
|
15,910
|
Enterprise Value (EV)
1 |
23,492
|
20,460
|
22,738
|
20,319
|
11,352
|
13,675
|
P/E ratio
|
-22.2
x
|
-17
x
|
-20
x
|
-14.8
x
|
-9.51
x
|
-15.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,031
x
|
28,478
x
|
186
x
|
1,208
x
|
3,361
x
|
383
x
|
EV / Revenue
|
1,761
x
|
23,463
x
|
161
x
|
1,082
x
|
2,410
x
|
329
x
|
EV / EBITDA
|
-17.8
x
|
-15.4
x
|
-17.5
x
|
-13
x
|
-5.87
x
|
-7.16
x
|
EV / FCF
|
-45.4
x
|
-33.2
x
|
-29.5
x
|
-20.3
x
|
-8.08
x
|
-11.1
x
|
FCF Yield
|
-2.2%
|
-3.01%
|
-3.39%
|
-4.93%
|
-12.4%
|
-8.98%
|
Price to Book
|
6.23
x
|
4.86
x
|
6.54
x
|
8.35
x
|
3.42
x
|
4.18
x
|
Nbr of stocks (in thousands)
|
173,129
|
188,129
|
188,586
|
198,948
|
229,109
|
229,248
|
Reference price
2 |
156.5
|
132.0
|
139.0
|
114.0
|
69.10
|
69.40
|
Announcement Date
|
27/03/19
|
24/03/20
|
30/03/21
|
25/03/22
|
15/03/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
13.34
|
0.872
|
140.9
|
18.77
|
4.711
|
41.55
|
EBITDA
1 |
-1,321
|
-1,329
|
-1,299
|
-1,559
|
-1,935
|
-1,911
|
EBIT
1 |
-1,428
|
-1,451
|
-1,466
|
-1,716
|
-2,123
|
-2,090
|
Operating Margin
|
-10,703.07%
|
-166,383.14%
|
-1,040.47%
|
-9,141.35%
|
-45,059.69%
|
-5,029.7%
|
Earnings before Tax (EBT)
1 |
-1,256
|
-1,445
|
-1,494
|
-1,742
|
-1,917
|
-1,276
|
Net income
1 |
-1,222
|
-1,407
|
-1,378
|
-1,531
|
-1,614
|
-1,046
|
Net margin
|
-9,162.92%
|
-161,356.19%
|
-978.05%
|
-8,154.1%
|
-34,258.46%
|
-2,518.65%
|
EPS
2 |
-7.062
|
-7.759
|
-6.939
|
-7.694
|
-7.266
|
-4.569
|
Free Cash Flow
1 |
-518
|
-615.7
|
-770.4
|
-1,002
|
-1,406
|
-1,228
|
FCF margin
|
-3,883%
|
-70,607.53%
|
-546.83%
|
-5,336.49%
|
-29,835.87%
|
-2,955.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/03/19
|
24/03/20
|
30/03/21
|
25/03/22
|
15/03/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3,603
|
4,373
|
3,476
|
2,361
|
4,479
|
2,235
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-518
|
-616
|
-770
|
-1,002
|
-1,406
|
-1,228
|
ROE (net income / shareholders' equity)
|
-26.2%
|
-29.8%
|
-27.7%
|
-39.5%
|
-38%
|
-22.8%
|
ROA (Net income/ Total Assets)
|
-18%
|
-17.5%
|
-15.5%
|
-21.8%
|
-23.9%
|
-21.3%
|
Assets
1 |
6,780
|
8,047
|
8,894
|
7,012
|
6,764
|
4,902
|
Book Value Per Share
2 |
25.10
|
27.10
|
21.30
|
13.70
|
20.20
|
16.60
|
Cash Flow per Share
2 |
21.20
|
24.20
|
16.80
|
12.60
|
20.70
|
3.920
|
Capex
1 |
20.1
|
48
|
183
|
241
|
255
|
102
|
Capex / Sales
|
151.04%
|
5,503.44%
|
129.67%
|
1,285.56%
|
5,405.43%
|
245.33%
|
Announcement Date
|
27/03/19
|
24/03/20
|
30/03/21
|
25/03/22
|
15/03/23
|
26/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -12.68% | 434M | | +21.06% | 46.93B | | +37.38% | 39.08B | | -8.39% | 38.48B | | +30.02% | 31.01B | | -12.26% | 26.14B | | +11.15% | 25.88B | | +35.07% | 12.53B | | -6.23% | 11.36B | | -12.31% | 10.65B |
Other Biotechnology & Medical Research
|